Study S002801

A Single-Centre, Open-Label Study of the Effect of UBT251 on Pharmacokinetics of an Oral Combination Contraceptive (Ethinylestradiol and Levonorgestrel) and Gastric Emptying in Women of Non-Childbearing Potential With Overweight or Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07710729
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: RECRUITING
Enrollment: 40
Start: 2026-07-17
Primary completion: 2027-04-27
Lead sponsor: Novo Nordisk A/S
Conditions: Overweight; Obesity
Interventions: DRUG:UBT251; DRUG:Oral contraceptive; DRUG:Acetaminophen
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1332-9333

Registered primary outcomes

AUC,EE,SS: The area under the EE plasma concentration time curve during a dosing interval at steady state [From pre-dose on Day 8 up to 157 days]
AUC ,LN,SS: The area under the LN plasma concentration time curve during a dosing interval at steady state [From pre-dose on Day 8 up to 157 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.